Coalition for Affordable T-DM1 Crown Use Request (for patents on cancer drug Kadcyla)
T-DM1, a drug for the treatment of stage 4 HER2+ breast cancer, costs £102,405, roughly 3.9 times the 2014 UK per capita income of £26,350.
The National Health Service delisted T-DM1 from the Cancer Drug Fund on 4 September 2015, leaving potentially 1,500 U.K. patients without access to treatment.
On 1 October 2015, the Coalition for Affordable T-DM1 — a group of cancer patients, doctors, and access to medicines advocates, sent a letter to Secretary of State for Health Jeremy Hunt asking that the UK Government authorise the manufacture or importation of generic versions of the expensive breast cancer treatment T-DM1 under the Crown Use provisions in the UK Patents Act 1977.
The Coalition is composed of various access to medicines groups and individuals who care about breast cancer patients in the UK.
For more information on the Coalition and the Crown Use Request, visit http://cancerunion.org/tdm1_uk.html.
Also visit the websites of the Coalition member organizations:
Union for Affordable Cancer Treatment (UACT), http://cancerunion.org
Knowledge Ecology International (KEI), http://keionline.org
Universities Allied for Essential Medicines (UAEM), http://uaem.org/
Open Knowledge Foundation, https://okfn.org/
Young Professionals Chronic Disease Network (YP-CDN), http://ypchronic.org/
Tags:Trastuzumab Emtansine (Chemical Compound),T-DM1,Kadcyla,Roche,Health,compulsory license,Coalition for Affordable T-DM1,Crown Use,knowledge ecology international,kei,uact,union for affordable cancer treatment,uaem,open knowledge,keieurope,yp-cdn